Immuno-Oncology Drugs in Adjuvant Lung: The Next Frontier in Strengthening Moats
The potential for Merck and Roche looks underappreciated.Innovation in immuno-oncology drugs has supported the moats for Merck & Co Inc. (MRK...
562 Views
Last Week in Event SPACE: MYOB, Lynas, Versum, Jardines
Last Week in Event SPACE ... Not a bad reward/risk as Manikay greenmails KKR's MYOB Group Ltd (MYO AU) offer. If the Malaysian government impasse...
283 Views
Bristol Myers Squib & Celgene–Starboard Objections Addressed Today- Successful Deal Closure Probable
The proposed Bristol Myers Squibb Co (BMY US) & Celgene Corp (CELG US) transaction announced in the first week of 2019, garnered many sceptical...
210 Views
Last Week in Event SPACE: Renault/Nissan, Bank Danamon, Kabu, Celgene, Intouch
Last Week in Event SPACE ... The eventual unwind of tension may involve an increase in Nissan Motor (7201 JP)'s stake in Renault SA (RNO FP) and a...
921 Views
Bristol-Myers Beats the Drum for Celgene in 4Q18 Earnings Call
Bristol Myers Squibb Co (BMY US) announced earnings for 4Q18 this morning followed by a conference call. Most metrics beat street expectations but...
1k Views